Literature DB >> 10725823

Itraconazole pulse therapy in chromoblastomycosis.

S P Kumarasinghe1, M P Kumarasinghe.   

Abstract

Although daily itraconazole has been used effectively in chromoblastomycosis, there is no record of pulse therapy for chromoblastomycosis. A 68-year-old woman with a history of slowly enlarging scaly plaque involving the left shoulder and lateral chest, presented to the dermatology clinic at General Hospital, Kalutara, Sri Lanka. Clinically chromoblastomycosis was suspected. Direct KOH smears showed sclerotic bodies and histology showed granulomata with characteristic brown spores. Itraconazole (Sporanox) 200 mg. b.i.d. orally was given for a week followed by 3 drug free weeks. This cycle was repeated for 6 months (i.e. 7 pulses). Clinical improvement was visible by 2 months. Scrapings and biopsy repeated 5 months after the commencement of treatment were negative for chromoblastomycosis. The lesion had clinically healed by 5 months. Examination 8 months after cessation of treatment did not show any recurrence. Itraconazole pulse therapy is cheaper than daily treatment but effective in chromoblastomycosis. The optimal dosage and end point of treatment need to be ascertained after a larger study.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10725823

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  5 in total

Review 1.  Chromoblastomycosis.

Authors:  Flavio Queiroz-Telles; Sybren de Hoog; Daniel Wagner C L Santos; Claudio Guedes Salgado; Vania Aparecida Vicente; Alexandro Bonifaz; Emmanuel Roilides; Liyan Xi; Conceição de Maria Pedrozo E Silva Azevedo; Moises Batista da Silva; Zoe Dorothea Pana; Arnaldo Lopes Colombo; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 2.  Melanized fungi in human disease.

Authors:  Sanjay G Revankar; Deanna A Sutton
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

3.  Chromoblastomycosis Caused by Phialophora richardsiae.

Authors:  Young-Min Son; Hong-Kyu Kang; So-Young Na; Hye-Young Lee; Jin-Ok Baek; Jong-Rok Lee; Joo-Young Roh; Yiel-Hea Seo
Journal:  Ann Dermatol       Date:  2010-08-05       Impact factor: 1.444

Review 4.  Chromoblastomycosis.

Authors:  Paweł M Krzyściak; Małgorzata Pindycka-Piaszczyńska; Michał Piaszczyński
Journal:  Postepy Dermatol Alergol       Date:  2014-10-22       Impact factor: 1.837

Review 5.  Chromoblastomycosis: an etiological, epidemiological, clinical, diagnostic, and treatment update.

Authors:  Arival Cardoso de Brito; Maraya de Jesus Semblano Bittencourt
Journal:  An Bras Dermatol       Date:  2018 Jul-Aug       Impact factor: 1.896

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.